Purple biotech to present data for its tri-specific antibody platform—captn-3—at the eortc-nci-aacr symposium on molecular targets and cancer therapeutics

Captn-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of t cells and nk cells to mount an optimal anti-tumoral immune response against cancer
NCI Ratings Summary
NCI Quant Ranking